Sensitivity of MLL-rearranged AML Cells to All-trans Retinoic Acid is Associated with the Level of H3K4me2 in the RARα Promoter Region

Overview

Journal Blood Cancer J

Date 2014 Apr 29

PMID 24769646

Citations 25

Authors

K Sakamoto

T Imamura

M Yano

H Yoshida

A Fujiki

Y Hirashima

H Hosoi

Affiliations

Soon will be listed here.

Abstract

All-trans retinoic acid (ATRA) is well established as differentiation therapy for acute promyelocytic leukemia (APL) in which the PML-RARα (promyelocytic leukemia-retinoic acid receptor α) fusion protein causes blockade of the retinoic acid (RA) pathway; however, in types of acute myeloid leukemia (AML) other than APL, the mechanism of RA pathway inactivation is not fully understood. This study revealed the potential mechanism of high ATRA sensitivity of mixed-lineage leukemia (MLL)-AF9-positive AML compared with MLL-AF4/5q31-positive AML. Treatment with ATRA induced significant myeloid differentiation accompanied by upregulation of RARα, C/EBPα, C/EBPɛ and PU.1 in MLL-AF9-positive but not in MLL-AF4/5q31-positive cells. Combining ATRA with cytarabine had a synergistic antileukemic effect in MLL-AF9-positive cells in vitro. The level of dimethyl histone H3 lysine 4 (H3K4me2) in the RARα gene-promoter region, PU.1 upstream regulatory region (URE) and RUNX1+24/+25 intronic enhancer was higher in MLL-AF9-positive cells than in MLL-AF4-positive cells, and inhibiting lysine-specific demethylase 1, which acts as a histone demethylase inhibitor, reactivated ATRA sensitivity in MLL-AF4-positive cells. These findings suggest that the level of H3K4me2 in the RARα gene-promoter region, PU.1 URE and RUNX1 intronic enhancer is determined by the MLL-fusion partner. Our findings provide insight into the mechanisms of ATRA sensitivity in AML and novel treatment strategies for ATRA-resistant AML.

Citing Articles

Synergistic Effects of the RAR Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation.

Fleischmann M, Bechwar J, Voigtlander D, Fischer M, Schnetzke U, Hochhaus A Cancers (Basel). 2024; 16(7).

PMID: 38610989 PMC: 11011083. DOI: 10.3390/cancers16071311.

Nanoparticle-encapsulated retinoic acid for the modulation of bone marrow hematopoietic stem cell niche.

Quartin E, Rosa S, Gonzalez-Anton S, Mosteo Lopez L, Francisco V, Duarte D Bioact Mater. 2024; 34:311-325.

PMID: 38274293 PMC: 10809008. DOI: 10.1016/j.bioactmat.2023.12.017.

Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A.

Xu Y, Wang Z, Zhang L, Gao C, Li F, Li X J Cancer. 2023; 14(7):1182-1194.

PMID: 37215441 PMC: 10197941. DOI: 10.7150/jca.83219.

Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters.

van Gils N, Verhagen H, Broux M, Martianez T, Denkers F, Vermue E iScience. 2022; 25(9):105013.

PMID: 36097617 PMC: 9463578. DOI: 10.1016/j.isci.2022.105013.

Co-existence of a novel translocation t(11;22)(q23;q12.1) with PML-RARA in acute promyelocytic leukemia: a case report.

Shin W, Kim J, Yoon S, Bang H, Won J, Song H Ann Hematol. 2022; 101(10):2369-2371.

PMID: 35780252 DOI: 10.1007/s00277-022-04911-x.

References

Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M . Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc. 2009; 131(48):17536-7. DOI: 10.1021/ja907055q. View

Fazi F, Zardo G, Gelmetti V, Travaglini L, Ciolfi A, Di Croce L . Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood. 2007; 109(10):4432-40. DOI: 10.1182/blood-2006-09-045781. View

Chim C, Wong S, Pang A, Chu P, Lau J, Wong K . Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia. Leukemia. 2005; 19(12):2241-6. DOI: 10.1038/sj.leu.2403937. View

Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner J . Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res. 2012; 4(3):247-56. PMC: 3426386. View

Schenk T, Chen W, Gollner S, Howell L, Jin L, Hebestreit K . Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012; 18(4):605-11. PMC: 3539284. DOI: 10.1038/nm.2661. View

Fang Y, Zhou X, Lin M, Ying M, Luo P, Zhu D . Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Mol Carcinog. 2010; 50(1):24-35. DOI: 10.1002/mc.20687. View

Stam R, Schneider P, Hagelstein J, van der Linden M, Stumpel D, de Menezes R . Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood. 2009; 115(14):2835-44. DOI: 10.1182/blood-2009-07-233049. View

Balgobind B, Raimondi S, Harbott J, Zimmermann M, Alonzo T, Auvrignon A . Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009; 114(12):2489-96. PMC: 2927031. DOI: 10.1182/blood-2009-04-215152. View

Martens J, Brinkman A, Simmer F, Francoijs K, Nebbioso A, Ferrara F . PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell. 2010; 17(2):173-85. DOI: 10.1016/j.ccr.2009.12.042. View

10.

Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z . PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet. 2007; 40(1):51-60. DOI: 10.1038/ng.2007.7. View

11.

Meyer C, Hofmann J, Burmeister T, Groger D, Park T, Emerenciano M . The MLL recombinome of acute leukemias in 2013. Leukemia. 2013; 27(11):2165-76. PMC: 3826032. DOI: 10.1038/leu.2013.135. View

12.

Ferrara F, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S . Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 2001; 61(1):2-7. View

13.

Koh C, Wang C, Ng C, Ito Y, Araki M, Tergaonkar V . RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes. Leukemia. 2013; 27(9):1793-802. DOI: 10.1038/leu.2013.200. View

14.

Nowak D, Stewart D, Koeffler H . Differentiation therapy of leukemia: 3 decades of development. Blood. 2009; 113(16):3655-65. PMC: 2943835. DOI: 10.1182/blood-2009-01-198911. View

15.

Schepers H, Wierenga A, van Gosliga D, Eggen B, Vellenga E, Schuringa J . Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007; 110(4):1317-25. DOI: 10.1182/blood-2006-10-052175. View

16.

Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X . The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood. 2011; 118(25):6544-52. PMC: 3242717. DOI: 10.1182/blood-2010-11-317909. View

17.

Okuno Y, Huang G, Rosenbauer F, Evans E, Radomska H, Iwasaki H . Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol. 2005; 25(7):2832-45. PMC: 1061634. DOI: 10.1128/MCB.25.7.2832-2845.2005. View

18.

Gombart A, Kwok S, Anderson K, Yamaguchi Y, Torbett B, Koeffler H . Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP epsilon and PU.1. Blood. 2003; 101(8):3265-73. DOI: 10.1182/blood-2002-04-1039. View

19.

Sharma S, Lee D, Li B, Quinlan M, Takahashi F, Maheswaran S . A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69-80. PMC: 2851638. DOI: 10.1016/j.cell.2010.02.027. View

20.

Iijima K, Honma Y, Niitsu N . Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid. Leuk Lymphoma. 2004; 45(5):1017-24. DOI: 10.1080/1042819031000163887. View